The First Crispr Treatment Is Making Its Way to Patients
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital
RBC Capital analyst Luca Issi maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report) on November 13 and set a price ...
Science Daily11h
New discovery enables gene therapy for muscular dystrophies, other disorders
StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.
New catheter technology promises safer and more efficient treatment of blood vessels
Each year, more than 200 million catheters are used worldwide to treat vascular diseases, including heart disease and artery ...
Clinical trial shows positive results for potential treatment to combat a rare immune-mediated disease
An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...
Promising Developments in Lexeo Therapeutics’ LX2006 Program Drive Buy Rating
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research ...
Q3 2024 Capricor Therapeutics Inc Earnings Call
Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc ...